Luni Emdad
Overview
Explore the profile of Luni Emdad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
5017
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oka T, Smith S, Son H, Lee T, Oliver-Garcia V, Mortaja M, et al.
J Clin Invest
. 2025 Jan;
135(1).
PMID: 39744942
The continuous rise in skin cancer incidence highlights an imperative for improved skin cancer prevention. Topical calcipotriol-plus-5-fluorouracil (calcipotriol-plus-5-FU) immunotherapy effectively eliminates precancerous skin lesions and prevents squamous cell carcinoma (SCC)...
2.
Boukerche H, Su Z, Emdad L, Sarkar D, Fisher P
Cancer Res
. 2024 Oct;
84(19):3312.
PMID: 39350667
No abstract available.
3.
Mannangatti P, Bhoopathi P, Kumar A, Das S, Emdad L, Fisher P
Adv Cancer Res
. 2024 Sep;
164:191-240.
PMID: 39306366
Focused ultrasound (FUS) combined with microbubble (MB) treatment is a promising strategy capable of accurately delivering molecular medicines and gene therapy to treat various disease states. The rapid progression and...
4.
Kumar A, Emdad L, Das S, Fisher P
Adv Cancer Res
. 2024 Sep;
164:111-190.
PMID: 39306365
Adoptive cell therapy using chimeric antigen receptor (CAR) technology has become mainstream by employing advanced engineering platforms to promote cancer immunotherapy. CAR T cells have shown remarkable efficacy in the...
5.
Maji S, Kumar A, Emdad L, Fisher P, Das S
Adv Cancer Res
. 2024 Jul;
161:321-365.
PMID: 39032953
Prostate cancer (PC) has a high propensity to develop bone metastases, causing severe pain and pathological fractures that profoundly impact a patients' normal functions. Current clinical intervention is mainly palliative...
6.
Bhoopathi P, Mannangatti P, Pradhan A, Kumar A, Maji S, Lang F, et al.
J Cell Physiol
. 2024 May;
239(8):e31302.
PMID: 38775127
Primary, glioblastoma, and secondary brain tumors, from metastases outside the brain, are among the most aggressive and therapeutically resistant cancers. A physiological barrier protecting the brain, the blood-brain barrier (BBB),...
7.
Bhoopathi P, Kumar A, Pradhan A, Maji S, Mannangatti P, Windle J, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 37935566
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer without effective therapies and with poor prognosis, causing 7% of all cancer-related fatalities in the USA. Considering the lack of effective...
8.
Maji S, Pradhan A, Kumar A, Bhoopathi P, Mannangatti P, Guo C, et al.
Proc Natl Acad Sci U S A
. 2023 Nov;
120(45):e2307094120.
PMID: 37922327
Bone metastasis is a frequent and incurable consequence of advanced prostate cancer (PC). An interplay between disseminated tumor cells and heterogeneous bone resident cells in the metastatic niche initiates this...
9.
Pradhan A, Modi J, Maji S, Kumar A, Bhoopathi P, Mannangatti P, et al.
Mol Cancer Ther
. 2023 Sep;
22(10):1115-1127.
PMID: 37721536
Genome-wide gene expression analysis and animal modeling indicate that melanoma differentiation associated gene-9 (mda-9, Syntenin, Syndecan binding protein, referred to as MDA-9/Syntenin) positively regulates melanoma metastasis. The MDA-9/Syntenin protein contains...
10.
Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy
Kumar A, Das S, Emdad L, Fisher P
Adv Cancer Res
. 2023 Sep;
160:253-315.
PMID: 37704290
Current treatment of solid tumors with standard of care chemotherapies, radiation therapy and/or immunotherapies are often limited by severe adverse toxic effects, resulting in a narrow therapeutic index. Cancer gene...